| Assessment Status | Rapid Review complete |
| HTA ID | 22003 |
| Drug | Cefiderocol |
| Brand | Fetcroja® |
| Indication | For the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options. Consideration should be given to official guidance on the appropriate use of antibacterial agents. |
| Assessment Process | |
| Rapid review commissioned | 10/01/2022 |
| Rapid review completed | 16/02/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of cefiderocol compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
The HSE has approved reimbursement following confidential price negotiations. March 2024
